3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
27
Breast Neoplasms
23
Ovarian Neoplasms
19
Triple Negative Breast Neoplasms
17
Endometrial Neoplasms
16
Lung Neoplasms
15
Parkinson Disease 4, Autosomal Dominant Lewy Body
12
Fallopian Tube Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
9
Neoplasm Metastasis
9
Neoplasms
6
Esophageal Neoplasms
6
Adenocarcinoma Of Esophagus
6
Stomach Neoplasms
4
Melanoma
4
Esophageal Squamous Cell Carcinoma
4
Cholangiocarcinoma
4
Uterine Cervical Neoplasms
3
Colorectal Neoplasms
3
Carcinoma
3
Uterine Neoplasms
2
Urinary Bladder Neoplasms
2
Peritoneal Neoplasms
2
Pathologic Complete Response
2
Head and Neck Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Ovarian Epithelial
2
Brenner Tumor
2
Anatomic Stage I Breast Cancer AJCC v8
2
Advanced Solid Tumour
2
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
Paclitaxel
×
30 days
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled